These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 7053859)

  • 1. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth.
    Coezy E; Borgna JL; Rochefort H
    Cancer Res; 1982 Jan; 42(1):317-23. PubMed ID: 7053859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cytotoxicity of tamoxifen and its principal metabolites in human breast cancer cell lines].
    Bachmann-Moisson N; Barberi-Heyob M; Merlin JL; Ledrich ML; Batt AM; Guillemin F
    Bull Cancer; 1996 Oct; 83(10):808-15. PubMed ID: 8952630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiestrogen binding in antiestrogen growth-resistant estrogen-responsive clonal variants of MCF-7 human breast cancer cells.
    Miller MA; Lippman ME; Katzenellenbogen BS
    Cancer Res; 1984 Nov; 44(11):5038-45. PubMed ID: 6488162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity.
    Murphy CS; Parker CJ; McCague R; Jordan VC
    Mol Pharmacol; 1991 Mar; 39(3):421-8. PubMed ID: 2005879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of two estrogen-responsive proteins by antiestrogens in R27, a tamoxifen-resistant clone of MCF7 cells.
    Vignon F; Lippman ME; Nawata H; Derocq D; Rochefort H
    Cancer Res; 1984 May; 44(5):2084-8. PubMed ID: 6713400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiestrogenic potency and binding characteristics of the triphenylethylene H1285 in MCF-7 human breast cancer cells.
    Sheen YY; Ruh TS; Mangel WF; Katzenellenbogen BS
    Cancer Res; 1985 Sep; 45(9):4192-9. PubMed ID: 4040807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of basic side chain derivatives of Analog II as pure antiestrogens and antitumor agents.
    Magarian RA; Avor KS; Overacre LB; Kunchandy J; Paxton TR
    Anticancer Drug Des; 1995 Jun; 10(4):311-31. PubMed ID: 7786397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of different combinations of tamoxifen and toremifene on estrogen receptor-positive breast cancer cell lines.
    Coradini D; Biffi A; Cappelletti V; Di Fronzo G
    Cancer Detect Prev; 1995; 19(4):348-54. PubMed ID: 7553677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions of antiestrogens with human breast cancer in long-term tissue culture.
    Lippman M; Bolan G; Huff K
    Cancer Treat Rep; 1976 Oct; 60(10):1421-9. PubMed ID: 1035504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse.
    Gottardis MM; Robinson SP; Satyaswaroop PG; Jordan VC
    Cancer Res; 1988 Feb; 48(4):812-5. PubMed ID: 3338079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells.
    Katzenellenbogen BS; Norman MJ; Eckert RL; Peltz SW; Mangel WF
    Cancer Res; 1984 Jan; 44(1):112-9. PubMed ID: 6537799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of biologically active metabolites of tamoxifen on the proliferation kinetics of MCF-7 human breast cancer cells in vitro.
    Reddel RR; Murphy LC; Sutherland RL
    Cancer Res; 1983 Oct; 43(10):4618-24. PubMed ID: 6883318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen receptor-mediated and cytotoxic effects of the antiestrogens tamoxifen and 4-hydroxytamoxifen.
    Taylor CM; Blanchard B; Zava DT
    Cancer Res; 1984 Apr; 44(4):1409-14. PubMed ID: 6704959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Species-specific pharmacology of antiestrogens: role of metabolism.
    Jordan VC; Robinson SP
    Fed Proc; 1987 Apr; 46(5):1870-4. PubMed ID: 3556610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites.
    Liu X; Pisha E; Tonetti DA; Yao D; Li Y; Yao J; Burdette JE; Bolton JL
    Chem Res Toxicol; 2003 Jul; 16(7):832-7. PubMed ID: 12870885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on the ligand specificity and potential identity of microsomal antiestrogen-binding sites.
    Watts CK; Sutherland RL
    Mol Pharmacol; 1987 May; 31(5):541-51. PubMed ID: 3553893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance.
    Johnston SR; Lu B; Scott GK; Kushner PJ; Smith IE; Dowsett M; Benz CC
    Clin Cancer Res; 1999 Feb; 5(2):251-6. PubMed ID: 10037172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physicochemical and genetic evidence for specific antiestrogen binding sites.
    Faye JC; Jozan S; Redeuilh G; Baulieu EE; Bayard F
    Proc Natl Acad Sci U S A; 1983 Jun; 80(11):3158-62. PubMed ID: 6574477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of estrogen and progestin receptor concentrations in an experimental rat prostatic carcinoma by estrogen, antiestrogen, and progesterone.
    Mobbs BG; Johnson IE; DeSombre ER; Toth J; Hughes A
    Cancer Res; 1987 May; 47(10):2645-51. PubMed ID: 3552202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tamoxifen derivatives for delivery of the antitumoral (DACH)Pt group: selective synthesis by McMurry coupling, and biochemical behaviour.
    Top S; Kaloun el B; Vessières A; Leclercq G; Laïos I; Ourevitch M; Deuschel C; McGlinchey MJ; Jaouen G
    Chembiochem; 2003 Aug; 4(8):754-61. PubMed ID: 12898627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.